Prophylaxis of neutropenia with mecapegfilgrastim in patients with non-myeloid malignancies

Clinical study on the safety and efficacy of thiofegastine in the prevention of moderate and severe neutropenia associated with radiotherapy and chemotherapy in tumor patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200060208

Enrollment

Unknown

Registered

2022-05-22

Start date

2022-05-10

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

tumor

Interventions

Prevention group:PEG-rhG-CSF

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.The patient signed an informed consent form and volunteered to join this study. two. 2.Diagnosis of non-myeloid malignant tumors by pathology or histopathology (including solid tumors and malignant hematological tumors). 3. The researchers determined that patients could be given thiophagastine. 4. Age >= 18 years.

Exclusion criteria

Exclusion criteria: 1. Pregnant or lactating women. two. 2. Allergic to thiophagastine, polyethylene glycol recombinant human granulocyte stimulating factor, recombinant human granulocyte stimulating factor and other preparations expressed in Escherichia coli. 3. The researchers judged other situations that were not suitable for inclusion in the study.

Design outcomes

Primary

Measure	Time frame
Myelosuppression grade;	—

Countries

China

Contacts

Public ContactYan Maohui

Air Force Medical Center, the Chinese People's Liberation Army

yanmaohui1984@sina.com+86 18301071600

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026